Because in vitro studies suggest that PPARγ agonists may exert dual effects on prostate cancer (21), the clinical impact of the use of rosiglitazone depends on the trade-off between these dual effects of PPARγ agonists. The gene discussed is PPARG; the disease is prostate carcinoma.